ethopropazine (parsidol) Report issue

Small molecule Approved FDA
ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Ethopropazine is an anticholinergic drug. Ethopropazine is an inhibitor of butyrylcholinesterase and non-selective muscarinic acetylcholine receptor antagonist. Ethopropazine has been used for the treatment of parkinsonism and drug-induced extrapyramidal reactions. Also It used for the symptomatic treatment of hepatolenticular degeneration and congenital athetosis.   NCATS

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Discontinued
  • Delivery Methods: Oral
  • Pro Drug: No

Alternative names

10-[2-(diethylamino)-1-propyl]phenothiazine | 10-[2-(diethylamino)-2-methylethyl]phenothiazine | 10-(2-diethylaminopropyl)phenothiazine | 10-[2-(diethylamino)propyl]phenothiazine | 10h-phenothiazine-10-ethanamine, n,n-diethyl-alpha-methyl- | 2-diethylamino-1-propyl-n-dibenzoparathiazine | ethapropazine | ethopromazine | ethopropazine | ethopropazine hcl | ethopropazine hydrochloride | isopthazine | isothazine | isothiazine | lysivane | n,n-diethyl-1-(10h-phenothiazin-10-yl)-2-propanamine | n,n-diethyl-alpha-methyl-10h-phenothiazine-10-ethanamine | parsidol | parsitan | profenamina | profenamine | profenamine hcl | profenamine hibenzate | profenamine hydrochloride | profenaminum | prophenamine hcl

Organizations (2)

Research & Development (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (4)

Approved Indications (4)


 

Athetosis

Basal Ganglia Diseases

Hepatolenticular Degeneration

Parkinson Disease

Experimental Indications - Clinical Trial Phases 1-4 (0)

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue